Phase II trial of the addition of Lapatinib to Capecitabine versus Capecitabine alone as radio-sensitizers in KRAS wild type resectable rectal cancer

Trial Profile

Phase II trial of the addition of Lapatinib to Capecitabine versus Capecitabine alone as radio-sensitizers in KRAS wild type resectable rectal cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms LaRRC
  • Most Recent Events

    • 23 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top